trending Market Intelligence /marketintelligence/en/news-insights/trending/bBxRNrJalmuncGWutza7bg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Bausch Health's marketing application for acne lotion accepted by US FDA

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Bausch Health's marketing application for acne lotion accepted by US FDA

The U.S. Food and Drug Administration has accepted the marketing application for an acne treatment developed by Bausch Health Cos. Inc. and its dermatology business Ortho Dermatologics Inc., called IDP-123.

IDP-123, or tazarotene 0.045%, will be the first tazarotene acne treatment available in a lotion form if it gains approval from the U.S. regulator.

Acne occurs when hair follicles become plugged with oil and skin cells, leading to whiteheads, blackheads or pimples on the face, forehead, chest, upper back and shoulders. The skin condition — one of the most common in the U.S. — affects up to 50 million Americans, according to an Aug. 7 news release.

The new drug application for IDP-123 is based on data from two phase 3 studies, which showed that treatment with IDP-123 significantly improved the severity of noninflammatory and inflammatory lesions compared to placebo.